OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

Biotechnology

OcuTerra Therapeutics

Susannah Sinozich

David J. Tanzer

Bill Steinkrauss

The Clinical and Medical Affairs Team at OcuTerra Therapeutics oversees the strategic planning and execution of clinical trials for OTT166, ensuring regulatory compliance, patient safety, and robust data collection. They provide medical expertise, liaise with healthcare professionals, and drive the advancement of the novel eye drop treatment for diabetic eye disease.

Clinical and Medical Affairs Team

About

Team members

Other teams at OcuTerra Therapeutics

Advisory Team

Leadership Team